Keyword Analysis & Research: sanofi regeneron
Keyword Research: People who searched sanofi regeneron also searched
Search Results related to sanofi regeneron on Search Engine
-
Press Release: Sanofi grants Regeneron worldwide exclusive …
https://www.sanofi.com/en/media-room/press-releases/2022/2022-06-02-11-30-00-2455080
WEBJun 2, 2011 · Download PDF. Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (cemiplimab) Sanofi will receive an upfront payment of $900 million, and an 11% royalty on worldwide net sales of Libtayo. Sanofi will also be entitled to a $100 million regulatory milestone payment as well as sales-related milestone payments of up to $100 ...
DA: 41 PA: 41 MOZ Rank: 95
-
Sanofi, Regeneron uncouple on long-standing drug partnership, splitting …
https://www.fiercepharma.com/pharma/sanofi-regeneron-look-to-uncouple-longstanding-antibody-drug-partnership
WEBDec 10, 2019 · Sanofi may look to raise capital by selling its more than 23.5 million shares in Regeneron once the collaboration expires in 2020, the company said. The company announced the move as part of...
DA: 39 PA: 96 MOZ Rank: 86
-
Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data
https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-regenerons-dupixent-meets-endpoints-clinical-trial-2023-03-23/
WEBMar 23, 2023 · Shares in Sanofi and Regeneron surged after they said in a joint statement on Thursday a Phase III trial involving 939 current or former smokers also showed improvements in lung function,...
DA: 93 PA: 50 MOZ Rank: 11
-
FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For
https://finance.yahoo.com/news/fda-approves-regeneron-sanofis-sarilumab-172834608.html
WEBMarch 1, 2023 at 9:28 AM · 1 min read. The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Kevzara (sarilumab) for polymyalgia rheumatica (PMR), an...
DA: 40 PA: 86 MOZ Rank: 42
-
Regeneron Completes Purchase of Sanofi's Stake in Libtayo® …
https://investor.regeneron.com/news-releases/news-release-details/regeneron-completes-purchase-sanofis-stake-libtayor-cemiplimab
WEBTARRYTOWN, N.Y., July 1, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has completed the acquisition of Sanofi's stake in Libtayo ® (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in …
DA: 33 PA: 78 MOZ Rank: 53
-
Regeneron's Sanofi deal finally turns a profit, thanks to Dupixent
https://www.fiercepharma.com/pharma/more-than-a-decade-sanofi-and-regeneron-hit-profitability-antibody-partnership
WEBAug 6, 2019 · Fueled by Dupixent's $557 million in second-quarter sales, Regeneron on Tuesday reported that its Sanofi antibody partnership posted a $39 million profit, a big turnabout from the same period...
DA: 64 PA: 91 MOZ Rank: 44
-
Press Release: Dupixent® (dupilumab) approved by FDA as the ... - Sanofi
https://www.sanofi.com/en/media-room/press-releases/2022/2022-09-28-22-05-26-2524764
WEBSep 28, 2022 · President and Chief Scientific Officer, Regeneron. “Patients living with prurigo nodularis must often contend with dozens, if not hundreds, of itchy and painful nodules covering their body and have not had an approved treatment option for their disease.
DA: 77 PA: 46 MOZ Rank: 40
-
Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi …
https://investor.regeneron.com/news-releases/news-release-details/regeneron-strengthens-commitment-oncology-through-purchase
WEBJun 2, 2022 · Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer. Regeneron will secure global rights to Libtayo from Sanofi in exchange for upfront payment of $900 million, plus royalties and …
DA: 69 PA: 98 MOZ Rank: 5
-
Sanofi and Regeneron announce intent to restructure Antibody
https://www.sanofi.com/en/media-room/press-releases/2019/2019-12-10-13-30-00-1958553
WEBDec 10, 2019 · PARIS (FRANCE) AND TARRYTOWN, NY - December 10, 2019 – Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced their intent to simplify their antibody collaboration for Kevzara ® (sarilumab) and Praluent ® (alirocumab) by restructuring into a royalty-based agreement. Under the proposed restructuring, Sanofi is …
DA: 19 PA: 54 MOZ Rank: 3
-
FDA speeds Sanofi, Regeneron’s application for Dupixent in COPD
https://www.fiercepharma.com/pharma/sanofi-regeneron-get-step-closer-dupixent-copd-nod-fda-priority-review
WEBFeb 22, 2024 · Regeneron and Sanofi have reached another milestone as they look to add to their megablockbuster immunology drug Dupixent a new U.S. indication for uncontrolled chronic obstructive pulmonary...
DA: 66 PA: 67 MOZ Rank: 71
